Understanding vision loss in Usher syndrome type 1B
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Usher syndrome type 1 (USH1) in both eyes, with genetic changes in the MYO7A gene.
- You are at least 3 years old.
- If participating in special vision tests, you are between 18 and 75 years old and have a cochlear implant to hear instructions.
- You are enrolled in French social security or a similar system.
- You are not currently in an experimental treatment trial or have been in the previous MYO7A gene therapy trial (USHSTAT).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
This study follows people with Usher syndrome over time to better understand how hearing and vision symptoms change. It may help researchers measure disease progression and support future treatments.
This trial tests an experimental gene therapy given as an injection under the retina. It aims to slow or stop vision loss in people with Usher syndrome type 1B, a rare genetic condition that causes both hearing and vision problems.
This trial tests a new way to diagnose a specific form of retinitis pigmentosa (an eye disease that causes vision loss) linked to changes in the USH2A gene. The goal is to improve how doctors identify and track this condition.
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.